Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  JAMA ophthalmology

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaophthalmol.2014.5373PMID 25569026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GENETIC POLYMORPHISMS AND RETINOPATHY OF PREMATURITY

  2015cited by this paper
• Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.

  2014cited by this paper
• An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.

  2013cited by this paper
• Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.

  2012cited by this paper
• Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

  2012cited by this paper
• Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation

  2012cited by this paper
• Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

  2011cited by this paper
• On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review

  2011cited by this paper
• Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity.

  2011cited by this paper
• Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

  2011cited by this paper
• Effect of the oxygen saturation target on clinical characteristics of early- versus late-onset retinopathy of prematurity.

  2011cited by this paper
• Erythropoietin and retinopathy of prematurity.

  2011cited by this paper
• Significance of portal venous VEGF during liver regeneration after hepatectomy.

  2010cited by this paper
• A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity.

  2009cited by this paper
• Local VEGF Administration Enhances Healing of Colonic Anastomoses in a Rabbit Model

  2009cited by this paper
• Risk factors and growth factors in ROP.

  2009cited by this paper
• Pulmonary Vascular Endothelial Growth Factor Expression and Disaturated Phospholipid Content in a Chicken Model of Hypoxia-Induced Fetal Growth Restriction

  2009cited by this paper
• Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair.

  2009cited by this paper
• Neuroprotection using gene therapy to induce vascular endothelial growth factor-A expression

  2009cited by this paper
• Is ethnicity a risk factor for severe retinopathy of prematurity?

  2009cited by this paper
• Hsp20‐Engineered Mesenchymal Stem Cells Are Resistant to Oxidative Stress via Enhanced Activation of Akt and Increased Secretion of Growth Factors

  2009cited by this paper
• Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.

  2009cited by this paper
• Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity.

  2009cited by this paper
• Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson's disease

  2009cited by this paper
• Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity.

  2008cited by this paper
• Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture.

  2008cited by this paper
• VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity

  2008cited by this paper
• Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease.

  2008cited by this paper
• Is Pacific race a retinopathy of prematurity risk factor?

  2005cited by this paper
• Genetic polymorphisms and retinopathy of prematurity.

  2004cited by this paper
• Vascular endothelial growth factor: basic science and clinical progress.

  2004cited by this paper
• Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

  2004cited by this paper
• Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

  2004cited by this paper
• Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial.

  2003cited by this paper
• Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

  2002cited by this paper
• Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium--derived factor in brown norway and sprague dawley rats contributing to different susceptibilities to retinal neovascularization.

  2002cited by this paper
• VEGF and the quest for tumour angiogenesis factors

  2002cited by this paper
• Pitfalls in the measurement of circulating vascular endothelial growth factor.

  2001cited by this paper
• Vascular-specific growth factors and blood vessel formation

  2000cited by this paper
• Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?

  2000cited by this paper
• Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.

  1998cited by this paper
• Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease.

  1998cited by this paper
• Peripheral Blood Platelets Express VEGF-C and VEGF which Are Released during Platelet Activation

  1998cited by this paper
• In vitro release of vascular endothelial growth factor during platelet aggregation.

  1998cited by this paper
• Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity.

  1996influential reference
• Vascular endothelial growth factor is a secreted angiogenic mitogen.

  1989cited by this paper
• Epidemiology of retinopathy of prematurity.

  1988cited by this paper

• Design and evaluation of semi-solid lipid implants for controlled intravitreal release of bevacizumab.

  2026cites this paper
• Development of rapamycin-loaded PLGA nanoparticles for treating retinopathy of prematurity.

  2025cites this paper
• Reactivation of retinopathy of prematurity after anti-VEGF treatment: a review

  2025cites this paper
• Different ranibizumab dosages for retinopathy of prematurity: 5-year follow-up data of the randomised, controlled CARE-ROP Study

  2025cites this paper
• Impacts of sulfate polysaccharide JCS1S2 on retinal neovascularization in oxygen-induced retinopathy rats

  2025cites this paper
• Role of Preoperative and Postoperative Intravitreal Anti-VEGF Agents in Managing Diabetic Macular Edema and Diabetic Retinopathy

  2025cites this paper
• A meta-analysis of intravitreal ranibizumab versus laser photocoagulation for the treatment of retinopathy of prematurity.

  2025cites this paper
• Retinopathy of Prematurity (ROP): An Overview of Biomarkers in Various Samples for Prediction, Diagnosis, and Prognosis

  2025cites this paper
• Circulating VEGF-A Levels in Relation to Retinopathy of Prematurity and Treatment Effects: A Systematic Review and Meta-Analysis

  2024cites this paper
• Relations between Neurocognitive Function and Visual Acuity: A Cross-Sessional Study in a Cohort of Premature Children

  2024cites this paper
• ADMINISTERING INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY

  2024cites this paper
• Bevacizumab for Retinopathy of Prematurity is Not Associated With Systemic Hypertension.

  2024cites this paper
• Targeting adenosine A2A receptors for early intervention of retinopathy of prematurity

  2024cites this paper
• Aflibercept to treat retinopathy of prematurity: need for more research

  2024cites this paper
• Term infant brain MRI after ROP treatment by anti-VEGF injection versus laser therapy.

  2024cites this paper
• Ocular and developmental outcomes of a dosing study of bevacizumab for retinopathy of prematurity.

  2023cites this paper
• Pathophysiology of Retinopathy of Prematurity.

  2023cites this paper
• SYVN1 Promotes STAT3 Protein Ubiquitination and Exerts Antiangiogenesis Effects in Retinopathy of Prematurity Development

  2023cites this paper
• The Long-Term Observation of the Beneficial Effects of Treatment: 0.12 mg Anti-VEGF Monotherapy or Anti-VEGF Combined Therapy and Diode-Laser in Various Stages of Retinopathy of Prematurity—Series of Cases

  2023cites this paper
• Research hotspots and trends in retinopathy of prematurity from 2003 to 2022: a bibliometric analysis

  2023cites this paper
• An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity

  2023cites this paper
• Comparison of Bevacizumab and Aflibercept for Suppression of Angiogenesis in Human Retinal Microvascular Endothelial Cells

  2023cites this paper
• Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity

  2023cites this paper
• Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries

  2023cites this paper
• Systemic Cytokines in Retinopathy of Prematurity

  2023cites this paper
• Changes in Serum Concentrations of Vascular Endothelial Growth Factors-A and B after Intravitreal Injection of Ranibizumab and Conbercept for Retinopathy of Prematurity

  2023cites this paper
• Long-Term Visual Prognosis of Patients Following Lens-Sparing Vitrectomy for Stage 4A Retinopathy of Prematurity

  2023cites this paper
• Evaluation of babies with retinopathy of prematurity following intravitreal bevacizumab administration

  2023cites this paper
• Seven-year follow-up of a pediatric patient with combined hamartoma of retina and retinal pigment epithelium complicating with preretinal neovascularization and vitreous hemorrhage treated with intravitreal injections of bevacizumab

  2022influential citation
• Retinopathy of prematurity: A review of pathophysiology and signaling Pathways

  2022cites this paper
• Retinopathy of prematurity: Metabolic risk factors

  2022cites this paper
• Neurodevelopmental Outcomes for Retinopathy of Prematurity: A Nationwide Database Study.

  2022cites this paper
• Pulmonary function in school-age children following intravitreal injection of bevacizumab for retinopathy of prematurity

  2022cites this paper
• Pulmonary Hypertension and Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity-Is There a Link?

  2022cites this paper
• Pulmonary Hypertension in Preterm Infants Treated With Laser vs Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.

  2022cites this paper
• Systematic review of the guidelines for retinopathy of prematurity

  2022cites this paper
• Postnatal Growth Trajectories and Neurodevelopmental Outcomes Following Bevacizumab Treatment for Retinopathy of Prematurity

  2022cites this paper
• Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.

  2022cites this paper
• A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept and Laser for Retinopathy of Prematurity.

  2022cites this paper
• Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal study

  2022cites this paper
• Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.

  2022cites this paper
• Low-dose ranibizumab administration in retinopathy of prematurity

  2022cites this paper
• Safety and outcomes of intravitreal aflibercept in diabetic macular edema - a systematic review.

  2022cites this paper
• Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity

  2022cites this paper
• Inter-eye comparison of retinal vascular growth rate and angiographic findings following unilateral bevacizumab treatment

  2021cites this paper
• Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again

  2021influential citation
• Neurodevelopmental Outcomes in Preterm Infants with Retinopathy of Prematurity.

  2021cites this paper
• Systemic conbercept pharmacokinetics and VEGF pharmacodynamics following intravitreal injections of conbercept in patients with retinopathy of prematurity

  2021cites this paper
• Neurodevelopmental Outcomes Associated With Intravitreal Bevacizumab Injections for Retinopathy of Prematurity

  2021cites this paper
• The Effect of Intravitreal Bevacizumab Dose on Retinal Vascular Progression in Retinopathy of Prematurity

  2021cites this paper
• Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy

  2021cites this paper
• The Use of Bevacizumab in the Treatment of Retinopathy of Prematurity.

  2021cites this paper
• Low-Dose Ranıbızumab Admınıstratıon in Retınopathy of Prematurıty

  2021cites this paper
• Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF).

  2021cites this paper
• Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of Prematurity.

  2021cites this paper
• Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the Primary Modality of Treatment

  2021cites this paper
• Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity

  2021cites this paper
• Cognitive Outcomes Following Intravitreal Bevacizumab for Retinopathy of Prematurity: 4- to 6-Year Outcomes in a Prospective Cohort.

  2021cites this paper
• Complications of retinopathy of prematurity treatment

  2021cites this paper
• INTRAVITREAL RANIBIZUMAB INJECTION AS TREATMENT IN PATIENTS WITH TYPE 1 RETINOPATHY OF PREMATURITY

  2021cites this paper
• Neurodevelopmental Outcomes Following Anti-VEGF Treatment for ROP

  2021cites this paper
• FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY

  2021cites this paper
• Association of Systemic or Intravitreal Antivascular Endothelial Growth Factor (Anti-VEGF) and Impaired Wound Healing in Pediatric Patients

  2021cites this paper
• Protective effects of rapamycin on the retinal vascular bed during the vaso‐obliteration phase in mouse oxygen‐induced retinopathy model

  2020cites this paper
• [Retinopathy of prematurity: from prevention to treatment].

  2020cites this paper
• Two-Year Outcomes Comparing Anti-VEGF Injections to Laser for ROP Using a Commercial Claims Database.

  2020cites this paper
• Gene expression profile analysis of the rabbit retinal vein occlusion model

  2020cites this paper
• Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity.

  2020cites this paper
• Update in the Treatment of Retinopathy of Prematurity

  2020cites this paper
• The Short-Term Effects of Intravitreal Injection of Bevacizumab on the Plasma Levels of Vascular Endothelial Growth Factor, Insulin-Like Growth Factor-1, and Growth Parameters in Infants with Retinopathy of Prematurity

  2020cites this paper
• Neurodevelopmental Outcomes Following Intravitreal Bevacizumab With Laser Versus Laser Photocoagulation Alone for Retinopathy of Prematurity.

  2020cites this paper
• Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines

  2020cites this paper
• Strategies to Prevent Severe Retinopathy of Prematurity: A 2020 Update and Meta-analysis.

  2020cites this paper
• Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions

  2020cites this paper
• ANATOMICAL AND FUNCTIONAL RESULTS OF INTRAVITREAL AFLIBERCEPT MONOTHERAPY FOR TYPE 1 RETINOPATHY OF PREMATURITY: One-Year Outcomes.

  2020cites this paper
• Serum VEGF and Ang-2 Levels in Infants Before and After Laser Treatment for Retinopathy of Prematurity

  2020cites this paper
• Retinopatía del prematuro: Actualización en detección y tratamiento

  2020cites this paper
• Retinal Detachment After Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.

  2020cites this paper
• Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis

  2020cites this paper
• Neurodevelopmental Outcomes After Bevacizumab Treatment for Retinopathy of Prematurity-A Meta-Analysis.

  2020cites this paper
• Rétinopathie du prématuré : de la prévention au traitement

  2020cites this paper
• Contralateral effect of systemic absorption of low dose bevacizumab (Avastin) after unilateral intravitreal injection in severe retinopathy of prematurity (ROP)

  2020cites this paper
• Delayed Laser photocoagulation following intravitreal anti–vascular endothelial growth factor injection allows immature retinal vessels to regrow without recurrence of retinopathy of prematurity

  2019cites this paper
• Association of preretinal hemorrhage with the presence and severity of retinopathy of prematurity in high-risk patients

  2019cites this paper
• Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression

  2019cites this paper
• Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety

  2019cites this paper
• EARLY VITAMIN A SUPPLEMENTATION IMPROVES THE OUTCOME OF RETINOPATHY OF PREMATURITY IN EXTREMELY PRETERM INFANTS

  2019cites this paper
• Optimizing Measurement of Vascular Endothelial Growth Factor in Small Blood Samples of Premature Infants

  2019cites this paper
• Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.

  2019cites this paper
• Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity

  2019cites this paper
• Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP.

  2019cites this paper
• The ameliorative effect of angiotensin 1-7 on experimentally induced-preeclampsia in rats: Targeting the role of peroxisome proliferator-activated receptors gamma expression & asymmetric dimethylarginine.

  2019cites this paper
• Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment

  2019cites this paper
• Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser

  2019cites this paper
• Retinopathy of Prematurity ; A Review

  2019cites this paper
• Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity

  2019cites this paper
• Comparison of Vascular Outgrowth Rate and Retinal Vascular Development Border after Intravitreal Injection of Aflibercept or Bevacizumab to Treat Retinopathy of Prematurity

  2019cites this paper
• Management of retinopathy of prematurity in a neonatal unit: Current approach

  2019cites this paper
• Involution of retinopathy of prematurity and neurodevelopmental outcomes after intravitreal bevacizumab treatment

  2019cites this paper
• Retinopathy of prematurity treatment: Asian perspectives

  2019cites this paper